Is Channel Therapeutics Corporation (CHRO) a Buy, Sell, or Hold?
AMEX : CHRO
Channel Therapeutics Corporation — Institutional Ownership
$1.35 USD
$0.09 (7.14%)
- Volume
- 193.12K
- Average Volume
- 76.4K
- Market Capitalization
- $8.9M
- P/E Ratio
- -0.05
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $54.29
- Year Low
- $1.23
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.79
Institutional Ownership Summary
Institutional Ownership %
%
Investors Holding
change: 0.0 | last:
Increased Positions
change: 0.0 | last:
Reduced Positions
change: 0.0 | last:
New Positions
change: 0.0 | last:
Sold Positions
change: 0.0 | last:
Total Calls
-
Total Puts
-
Put-Call Ratio
change: 0.0 | last:
Total Invested
-
Beneficial Ownership Filings
| Filing Date | Reporting Person | Amount Beneficially Owned | % of Class |
|---|---|---|---|
| 2026-05-15 | Ikarian Capital, LLC | 256.6K | 7.70% |
| 2026-05-07 | 3i, LP | 337.03K | 9.90% |
| 2026-02-17 | Ikarian Capital, LLC | 255.76K | 8.40% |
| 2026-02-05 | 3i, LP | 318.89K | 9.90% |
| 2025-11-14 | Murchinson Ltd. | 280K | 9.10% |
| 2025-11-14 | Ikarian Capital, LLC | 186.41K | 6.10% |
| 2025-11-10 | Ligand Pharmaceuticals Incorporated | 5.19M | 49.90% |
| 2025-08-13 | AME Equities LLC | - | 0.00% |
| 2025-07-08 | 3i, LP | 303.14K | 9.90% |
| 2025-07-03 | Key Recovery Group LLC | 40000.0 | 1.30% |
| 2025-07-03 | Ligand Pharmaceuticals Incorporated | 4.93M | 49.90% |
| 2025-07-03 | Balmoral Financial Group LLC | 92072.0 | 3.10% |
| 2025-07-03 | Ezra Friedberg | 250.12K | 8.30% |
| 2025-02-14 | Ikarian Capital, LLC | 440.85K | 7.30% |
| 2025-01-15 | Alexandra Wood (Canada) Inc. | 574.19K | 9.53% |
| 2024-03-04 | Boswell Prayer Ltd | 471.59K | 8.20% |
| 2024-03-04 | Boswell Prayer Ltd | 471.59K | 8.20% |
| 2024-03-04 | Rochelle Gross | 471.59K | 8.20% |
| 2024-03-04 | Rochelle Gross | 471.59K | 8.20% |
| 2024-03-01 | Ruth Friedman | 369.18K | 6.40% |
| 2024-03-01 | Benuvia Operations, LLC | 384.23K | 6.70% |
| 2024-03-01 | Aperture Healthcare Ventures Ltd. | 444.07K | 7.70% |
| 2024-03-01 | 3i, LP | 318.82K | 5.50% |
| 2024-03-01 | Aperture Healthcare Ventures Ltd. | 444.07K | 7.70% |
| 2024-03-01 | Waxcap Inc. | 41666.0 | 0.70% |
| 2024-03-01 | Benuvia Operations, LLC | 384.23K | 6.70% |
| 2024-03-01 | Ruth Friedman | 369.18K | 6.40% |
| 2024-03-01 | Darwin Richardson | 384.23K | 6.70% |
| 2024-03-01 | 3i Management LLC | 318.82K | 5.50% |
| 2024-03-01 | Maier Joshua Tarlow | 318.82K | 5.50% |
| 2024-03-01 | 3i, LP | 318.82K | 5.50% |
| 2024-03-01 | Maier Joshua Tarlow | 318.82K | 5.50% |
| 2024-03-01 | Motif Pharmaceuticals Ltd. | 483.41K | 8.40% |
| 2024-03-01 | Motif Pharmaceuticals Ltd. | 483.41K | 8.40% |
| 2024-03-01 | Waxcap Inc. | 41666.0 | 0.70% |
| 2024-03-01 | AME Equities LLC | 369.18K | 6.40% |
| 2024-03-01 | AME Equities LLC | 369.18K | 6.40% |
| 2024-03-01 | 3i Management LLC | 318.82K | 5.50% |
| 2024-03-01 | Darwin Richardson | 384.23K | 6.70% |
| 2024-02-26 | Balmoral Financial Group LLC | 520.72K | 9.00% |
| 2024-02-26 | Balmoral Financial Group LLC | 520.72K | 9.00% |
| 2024-02-26 | Ezra Friedberg | 545.72K | 9.50% |
| 2024-02-26 | Ezra Friedberg | 545.72K | 9.50% |
CHRO Enterprise Value History
Annual
| Date | Stock Price | Shares Outstanding | Market Cap | Cash & Equivalents | Total Debt | Enterprise Value |
|---|---|---|---|---|---|---|
| 2025-12-31 | $22.14 | 18.8M | $416.34M | $17.97M | $34.19M | $432.56M |
| 2024-12-31 | $6.41 | 5.57M | $35.73M | $513.44K | $2.19M | $37.4M |
| 2023-12-31 | $48.00 | 5.77M | $276.84M | $96391 | $1.27M | $278.01M |
| 2022-12-31 | $48.00 | 5.77M | $276.84M | $55074 | $540.43K | $277.33M |
| 2021-12-31 | $48.00 | 5.77M | $276.84M | -$ | $1.1M | $277.94M |
| 2020-12-31 | $48.00 | 5.77M | $276.84M | -$ | $241.79K | $277.08M |
Quarterly
| Date | Stock Price | Shares Outstanding | Market Cap | Cash & Equivalents | Total Debt | Enterprise Value |
|---|---|---|---|---|---|---|
| 2026-03-31 | $22.14 | 3.31M | $73.32M | $31.98M | $25.94M | $67.28M |
| 2025-12-31 | $22.14 | 18.8M | $416.34M | $17.97M | $34.19M | $432.56M |
| 2025-09-30 | $22.14 | 3.06M | $67.78M | $14.2M | $2.85M | $56.43M |
| 2025-06-30 | $12.60 | 640.52K | $8.07M | $59172 | $2.3M | $10.32M |
| 2025-03-31 | $14.20 | 6.13M | $87.02M | $131.32K | $2.5M | $89.39M |
| 2024-12-31 | $6.41 | 5.68M | $36.43M | $513.44K | $2.19M | $38.1M |
| 2024-09-30 | $7.10 | 5.79M | $41.13M | $1.25M | $2.29M | $42.16M |
| 2024-06-30 | $12.50 | 5.77M | $72.17M | $2.41M | $1.59M | $71.35M |
| 2024-03-31 | $23.90 | 5.77M | $137.82M | $3.77M | -$ | $134.05M |
| 2023-12-31 | $48.00 | 5.88M | $282.14M | $96391 | $1.27M | $283.31M |
| 2023-09-30 | $48.00 | 5.77M | $276.84M | $22786 | $1.2M | $278.02M |
| 2023-06-30 | $48.00 | 5.77M | $276.84M | $81893 | $983.36K | $277.74M |